The CASP6 Knockout A-549 Polyclonal Cells product comprises a polyclonal population of A-549 human lung adenocarcinoma cells engineered using CRISPR/Cas9 to disrupt the CASP6 gene, encoding caspase-6. This loss-of-function model is generated via targeted gene editing, yielding a heterogeneous population of cells with diverse mutations at the CASP6 locus, effectively abolishing functional caspase-6 expression. The knockout employs A-549 as the host cell background and is provided as proliferating polyclonal cells, suitable for direct experimental use.
The A-549 cell line was originally established from the lung carcinoma tissue of a 58-year-old male, displaying epithelial morphology and serving as a widely adopted model for human lung adenocarcinoma and alveolar epithelium. These cells retain critical features of malignant lung epithelial cells and are extensively used in cancer biology, drug sensitivity testing, and respiratory epithelial studies. Their robust growth and well-characterized signaling landscapes make them a reliable substrate for genetic perturbation and functional analyses.
Caspase-6 is a critical executioner caspase that functions downstream of initiator caspases in both intrinsic and extrinsic apoptotic pathways. It is activated by proteolytic cleavage mediated by caspase-8, caspase-9, caspase-10, or granzyme B, and its activity is inhibited by XIAP and survivin (BIRC5). Activated caspase-6 cleaves a repertoire of substrates including lamin A/C (LMNA), lamin B1 (LMNB1), cytokeratin 18 (KRT18), PARP1, and inhibitor of caspase-activated DNase (ICAD), leading to nuclear lamina breakdown, cytoskeletal dismantling, and DNA fragmentation. In addition to its roles in apoptosis, caspase-6 aberrantly processes proteins associated with neurodegeneration, such as huntingtin (HTT) and amyloid precursor protein (APP), contributing to aggregate formation and neuronal dysfunction. Interacting factors include HSPA5/BiP and BCL2 family members, positioning caspase-6 at the nexus of cell death and stress signaling.
In the A-549 lung adenocarcinoma context, disruption of CASP6 provides a defined genetic background to dissect apoptosis regulation and survival signaling in cancer cells. The knockout model facilitates studies on resistance to extrinsic death receptor ligands (TNF, TRAIL, FASL) and intrinsic mitochondrial-mediated apoptosis, both of which converge on caspase-6 activation. Because A-549 cells express relevant oncogenic drivers and have intact apoptotic machinery, this knockout system enables the identification of compensatory survival mechanisms and caspase-independent cell death pathways. Furthermore, given the emerging links between caspase-6 and neurodegenerative proteotoxicity, these cells offer a platform for exploring non-apoptotic functions of caspase-6 in stress responses and protein homeostasis within an epithelial tumor environment.
Typical applications of these polyclonal knockout cells include apoptosis mechanistic studies using flow cytometry-based Annexin V/propidium iodide staining and tetramethylrhodamine-based caspase activity assays, cell viability assessments via MTT or ATP-luminescence, and migration/invasion assays to evaluate metastatic potential. Gene expression profiling by RNA-seq or RT-qPCR quantifies transcriptional adaptations to CASP6 loss, while Western blotting validates the absence of full-length caspase-6 and appearance of cleaved substrates like PARP1 or lamin A. The model is also suited for drug screening to identify caspase-6-selective inhibitors, particularly in the context of cancer therapeutics or neuroprotective strategies. Investigators can leverage this product to explore the intersection of apoptosis, stress signaling, and epithelial tumor biology. For additional technical details or custom configurations, please contact Ascent Research.
